利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.033 秒)

    &agr;v integrin receptor antagonists
    1.
    发明授权
    &agr;v integrin receptor antagonists 失效
    alphav整合素受体拮抗剂

    公开(公告)号：US06410526B1

    公开(公告)日：2002-06-25

    申请号：US09583522

    申请日：2000-05-31

    申请人： Mark E. Duggan ,  George D. Hartman ,  Robert S. Meissner ,  James J. Perkins

    发明人： Mark E. Duggan ,  George D. Hartman ,  Robert S. Meissner ,  James J. Perkins

    IPC分类号： A61K3155

    CPC分类号： C07D239/48 ,  C07D401/06 ,  C07D471/04

    摘要： The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

    摘要翻译： 本发明涉及新的壬酸衍生物，它们的合成及其作为alphav整联蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是整联蛋白受体alphavbeta3和alphavbeta5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，炎症性关节炎 ，病毒性疾病，癌症和转移性肿瘤生长。

    N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
    2.
    发明申请
    N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators 审中-公开
    N-（吡啶-3-基）-2-苯基丁酰胺作为雄激素受体调节剂

    公开(公告)号：US20080124402A1

    公开(公告)日：2008-05-29

    申请号：US11666525

    申请日：2005-10-25

    申请人： Yuntae Kim ,  Joshua Close ,  Mark E. Duggan ,  Barbara Hanney ,  Robert S. Meissner ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    发明人： Yuntae Kim ,  Joshua Close ,  Mark E. Duggan ,  Barbara Hanney ,  Robert S. Meissner ,  Jeffrey Musselman ,  James J. Perkins ,  Jiabing Wang

    IPC分类号： A61K33/16 ,  C07D213/02 ,  A61K31/44 ,  A61K31/56 ,  A61K38/16 ,  A61K31/59 ,  A61P19/10 ,  A61P19/08 ,  A61K31/66 ,  A61K31/4535 ,  A61K33/10 ,  A61K33/06

    CPC分类号： C07D213/64 ,  A61K31/44 ,  C07D213/74

    摘要： Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

    摘要翻译： 结构式（I）的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

    Integrin receptor antagonists
    5.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号：US06268378B1

    公开(公告)日：2001-07-31

    申请号：US09498895

    申请日：2000-02-07

    申请人： Mark E. Duggan ,  Robert S. Meissner ,  James J. Perkins

    发明人： Mark E. Duggan ,  Robert S. Meissner ,  James J. Perkins

    IPC分类号： A61K314375

    CPC分类号： C07D401/14 ,  A61K31/66 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

    摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

    摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为玻连蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是玻连蛋白受体alphavbeta3和/或alphavbeta5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症， 病毒性疾病和肿瘤生长。

    Integrin receptor antagonists
    8.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号：US06211191B1

    公开(公告)日：2001-04-03

    申请号：US09212510

    申请日：1998-12-15

    申请人： Mark E. Duggan ,  James J. Perkins ,  Robert S. Meissner

    发明人： Mark E. Duggan ,  James J. Perkins ,  Robert S. Meissner

    IPC分类号： C07D40306

    CPC分类号： C07D471/04 ,  A61K41/00 ,  A61K45/06

    摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;&ngr;&bgr;3, &agr;&ngr;&bgr;5, and/or &agr;&ngr;&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

    摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为整联蛋白受体拮抗剂的用途。 更具体地，本发明的化合物是整联蛋白受体α3，α3，α5和/或α6β6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，并抑制血管再狭窄，糖尿病性视网膜病变， 黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。

    Integrin receptor antagonists
    9.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号：US06066648A

    公开(公告)日：2000-05-23

    申请号：US212123

    申请日：1998-12-15

    申请人： Mark E. Duggan ,  Robert S. Meissner ,  James J. Perkins

    发明人： Mark E. Duggan ,  Robert S. Meissner ,  James J. Perkins

    IPC分类号： A61K31/66 ,  A61K45/06 ,  C07D401/14 ,  C07D471/04 ,  C07D519/00 ,  A01N43/40

    CPC分类号： C07D401/14 ,  A61K31/66 ,  A61K45/06 ,  C07D471/04

    摘要： The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

    摘要翻译： 本发明涉及其化合物及其衍生物，其合成及其作为玻连蛋白受体拮抗剂的用途。 更具体地说，本发明的化合物是玻连蛋白受体αnββ3和/或αnuβ5的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病性视网膜病变，黄斑变性， 血管生成，动脉粥样硬化，炎症，病毒性疾病和肿瘤生长。